INSP

In Q1 and Q2 2026, Inspire Medical Systems reported EPS and revenues that exceeded analyst expectations, achieving profitability in Q2 due to reduced expenses, despite a 7.6% year-over-year revenue decline in Q2 attributed to coding and reimbursement disruptions. On August 3, 2026, the company announced "Project Horizon," a strategic growth plan. Insider selling was reported in August 2026. The stock experienced volatility, including a significant rally in September 2026, though it remained below its 52-week high. JPMorgan, Mizuho, Evercore ISI, and BofA raised price targets in August and September 2026, while Zacks Research downgraded the stock to "Hold" on September 24, 2026. Investor sentiment deteriorated in August 2026, leading to a 39% stock drop after an earnings miss and revised guidance, driven by ongoing coding and reimbursement uncertainty for the Inspire V system's CPT code 64582 with the -52 modifier. Despite challenges, the stock surged approximately 19% since the Q2 report and about 50% over the past 90 days (June-September 2026).